Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEA: Bevacizumab + Endocrine Therapy in Advanced Breast Cancer
NCT00545077Phase 3Completed
- Sponsor
- GEICAM
- Start
- Nov 2007
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00545077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00545077.